CA3052873C - Procedes de traitement de la maladie de crohn et de la rectocolite hemorragique - Google Patents

Procedes de traitement de la maladie de crohn et de la rectocolite hemorragique

Info

Publication number
CA3052873C
CA3052873C CA3052873A CA3052873A CA3052873C CA 3052873 C CA3052873 C CA 3052873C CA 3052873 A CA3052873 A CA 3052873A CA 3052873 A CA3052873 A CA 3052873A CA 3052873 C CA3052873 C CA 3052873C
Authority
CA
Canada
Prior art keywords
patient
weeks
upadacitinib
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3052873A
Other languages
English (en)
Other versions
CA3052873A1 (fr
Inventor
Roopal B. Thakkar
Steven JUNGERWIRTH
Ana Paula Machado de LACERDA
Anne M. ROBINSON
Jose Jeffrey V. ENEJOSA
Aileen L. Pangan
Mohamed-Eslam Mohamed
Ahmed Othman
Ayman D. Allian
Ben Klunder
Ahmad Y. Sheikh
Jayanthy Jayanth
Fredrik Lars NORDSTROM
Mathew M. Mulhern
Patrick J. Marroum
Peter T. Mayer
Thomas B. Borchardt
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc filed Critical AbbVie Inc
Priority claimed from PCT/US2018/021800 external-priority patent/WO2018165581A1/fr
Publication of CA3052873A1 publication Critical patent/CA3052873A1/fr
Application granted granted Critical
Publication of CA3052873C publication Critical patent/CA3052873C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

La présente invention concerne des procédés de traitement de la maladie de Crohn et, en particulier, des procédés pour induire une rémission clinique et/ou une amélioration endoscopique de la maladie de Crohn, au moyen d'un inhibiteur de JAK1. Dans certains modes de réalisation, on administre au patient une dose d'induction de l'inhibiteur de JAK1 pour induire une rémission clinique et/ou une amélioration endoscopique de la maladie de Crohn, suivie par l'administration d'au moins une dose de maintenance de l'inhibiteur de JAK1 par la suite. Dans d'autres modes de réalisation, la présente invention concerne des procédés de traitement de la rectocolite hémorragique au moyen d'un inhibiteur de JAK1.
CA3052873A 2017-03-09 2018-03-09 Procedes de traitement de la maladie de crohn et de la rectocolite hemorragique Active CA3052873C (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762469337P 2017-03-09 2017-03-09
US62/469,337 2017-03-09
US201762470565P 2017-03-13 2017-03-13
US62/470,565 2017-03-13
US201762483289P 2017-04-07 2017-04-07
US62/483,289 2017-04-07
US201762593629P 2017-12-01 2017-12-01
US62/593,629 2017-12-01
PCT/US2018/021800 WO2018165581A1 (fr) 2017-03-09 2018-03-09 Procédés de traitement de la maladie de crohn et de la rectocolite hémorragique

Publications (2)

Publication Number Publication Date
CA3052873A1 CA3052873A1 (fr) 2018-09-13
CA3052873C true CA3052873C (fr) 2025-10-21

Family

ID=

Similar Documents

Publication Publication Date Title
AU2024203642B2 (en) Methods of treating Crohn's disease and ulcerative colitis
US11564922B2 (en) Methods of treating crohn's disease and ulcerative colitis
AU2023251492B2 (en) Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11976077B2 (en) Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms therof
CA3052873C (fr) Procedes de traitement de la maladie de crohn et de la rectocolite hemorragique
HK40123037A (en) Methods of treating crohn's disease and ulcerative colitis
BR122022024891B1 (pt) Composição farmacêutica oral de liberação prolongada uma vez ao dia compreendendo (3s,4r)-3-etil-4-(3h-imidazo[1,2-a]pirrolo[2,3-e]pirazin-8-il)-n- (2,2,2-trifluoroetil)pirroli-dina-1-carboxamida
BR122022024934B1 (pt) Base livre amorfa do composto (3s,4r)-3-etil-4-(3h-imidazo[1,2- a]pirrolo [2,3-e]-pirazin-8-il)-n-(2,2,2-trifluoroetil)pirrolidina-1- carboxamida e composição farmacêutica contendo a mesma
BR122022024907B1 (pt) Anidrato cristalino do composto (3s,4r)-3-etil-4-(3h-imidazo[1,2-a] pirrolo[2,3-e]pirazin-8-il)-n-(2,2,2-trifluoroetil)pirrolidina-1-carboxamida
BR112018007677B1 (pt) Hemi-hidrato cristalino do composto (3s,4r)-3-etil-4-(3h-imidazo[1,2-a] pirrolo[2,3-e]pirazin-8-il)-n-(2,2,2-trifluoroetil)pirroli-dina-1-carboxamida
BR122022024919B1 (pt) Hidrato de tartarato cristalino do composto (3s,4r)-3-etil4-(3h-imidazo [1,2-a]pirrolo[2,3-e]pirazin-8-il)-n-(2,2,2-trifluoroetil)pirroli-dina-1-carboxamida